COSM News

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Form 8-K